Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. Liquidia has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia is also developing L606, an investigational liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer, for use in North America. The subsidiary Liquidia PAH provides for the commercialization of pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection.
Looking for a particular Liquidia Corporation employee's phone or email?
Liquidia Corporation Questions
The Liquidia Corporation annual revenue was $14.8 million in 2026.
Roger Jeffs is the CEO of Liquidia Corporation.
232 people are employed at Liquidia Corporation.
Liquidia Corporation is based in Morrisville, North Carolina.
The NAICS codes for Liquidia Corporation are [54, 541, 325413, 3254, 54183, 32541, 325, 541830, 5418, 32].
The SIC codes for Liquidia Corporation are [873, 87].
Top Liquidia Corporation Employees
-
Roger Jeffs
Chief Executive Officer at Liquidia Corporation
Chapel Hill, NC, US45+ -
Michael Kaseta
Chief Financial Officer and Chief Operating Officer at Liquidia Corporation
South Brunswick Township, NJ, US35+ -
Bruce Boucher
President and CFO at Liquidia Corporation
Durham, NC, US15 -
Frank Bartolini
Senior Vice President of Market Access at Liquidia Corporation
Morrisville, NC, US14 -
35+
-
Jason Adair
Chief Business Officer at Liquidia Corporation
Chapel Hill, NC, US25+ -
Rajeev Saggar
Chief Medical Officer at Liquidia Corporation
Phoenix, AZ, US25+ -
45+
-
Gareth Gwyn
Vice President Medical Affairs at Liquidia Corporation
Los Angeles, CA, US34 -
25+
Related Companies
